Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer's disease

Fioriti, L., Wijesekara, N., Argyrousi, E. K., Matsuzaki, S., Takamura, H., Satoh, K., Han, K., Yamauchi, H., Staniszewski, A., Acquarone, E., Orsini, F., Martucci, A., Katayama, T., Arancio, O., & Fraser, P. E. (2025). Genetic and pharmacologic enhancement of SUMO2 conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer’s disease. Alzheimer’s & Dementia, 21(3). Portico. https://doi.org/10.1002/alz.70030
Authors:
Luana Fioriti
Nadeeja Wijesekara
Elentina K Argyrousi
Shinsuke Matsuzaki
Hironori Takamura
Kanayo Satoh
Kyung Han
Hiroto Yamauchi
Agnieszka Staniszewski
Erica Acquarone
Franca Orsini
Annacarla Martucci
Taiichi Katayama
Ottavio Arancio
Paul E Fraser
Affiliated Authors:
Luana Fioriti
Elentina K Argyrousi
Agnieszka Staniszewski
Erica Acquarone
Ottavio Arancio
Columbia Affiliation:
Subjects:
Alzheimer Disease (MeSH)
Disease Models, Animal (MeSH)
Mice, Transgenic (MeSH)
Cognitive Dysfunction (MeSH)
Synapses (MeSH)
Author Keywords:
amyloid transgenic mouse model
behavioral analyses
biologic therapy
cognition
drug development
electrophysiology
preclinical testing
small ubiquitin-like modifiers
sumoylation
small ubiquitin‐like modifiers
elink
Publication Type:
Article
Unique ID:
10.1002/alz.70030
PMID:
40047257
DOI:
10.1002/alz.70030
Journal:
Alzheimer's and Dementia
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: